{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:24:46Z","timestamp":1789604686798,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JIMD Reports"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute hepatic porphyria (AHP) is a group of rare genetic diseases of heme biosynthesis resulting in severe neurovisceral attacks and chronic complications that negatively impact patients' well\u2010being. This study evaluated the impacts of AHP on patients' physical and emotional health from a global perspective. Adult patients from the United States, Italy, Spain, Australia, Mexico, and Brazil with AHP with &gt;1 porphyria attack within the past 2\u2009years or receiving intravenous hemin and\/or glucose for attack prevention completed an online survey assessing demographics, health characteristics, and patient\u2010reported outcomes. Results were analyzed collectively and by patient subgroups. Ninety\u2010two patients with AHP across the six countries completed the survey. More than 70% of patients reported that their physical, emotional, and financial health was fair or poor. Among patients who reported pain, fatigue, and muscle weakness, 94.3%, 95.6%, and 91.4%, respectively, reported that these symptoms limited daily activities. Moderate to severe depression was present in 58.7% of patients, and moderate to severe anxiety in 48.9% of patients. Of the 47% of patients who were employed, 36.8% reported loss in productivity while at work. Among patients, 85.9% reported that they had to change or modify goals that were important to them because of AHP. Aside from differences in healthcare utilization and pain severity, scores did not significantly vary with attack rate or use of hemin or glucose prophylactic treatments. AHP substantially impacts patients' physical and emotional well\u2010being, regardless of hemin or glucose prophylactic treatment or frequency of attacks. This multinational study demonstrates that there is substantial disease burden for patients with AHP, even among those experiencing sporadic attacks or using prophylactic treatment.<\/jats:p>","DOI":"10.1002\/jmd2.12343","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T23:44:40Z","timestamp":1666136680000},"page":"104-113","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Quantifying the impact of symptomatic acute hepatic porphyria on well\u2010being via patient\u2010reported outcomes: Results from the Porphyria Worldwide Patient Experience Research (<scp>POWER<\/scp>) study"],"prefix":"10.1002","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-9664","authenticated-orcid":false,"given":"Amy","family":"Dickey","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine Massachusetts General Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Wheeden","sequence":"additional","affiliation":[{"name":"American Porphyria Foundation  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Lyon","sequence":"additional","affiliation":[{"name":"American Porphyria Foundation  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Burrell","sequence":"additional","affiliation":[{"name":"Global Porphyria Advocacy Coalition  Durham City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hegarty","sequence":"additional","affiliation":[{"name":"Global Porphyria Advocacy Coalition  Durham City UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Falchetto","sequence":"additional","affiliation":[{"name":"Swiss Society for Porphyria  Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edrin R.","family":"Williams","sequence":"additional","affiliation":[{"name":"American Porphyria Foundation  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-8824","authenticated-orcid":false,"given":"Jasmin","family":"Barman\u2010Aks\u00f6zen","sequence":"additional","affiliation":[{"name":"Swiss Society for Porphyria  Z\u00fcrich Switzerland"},{"name":"Institute of Laboratory Medicine, Department of Medical Institutes Stadtspital Z\u00fcrich, Triemli  Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"DeCongelio","sequence":"additional","affiliation":[{"name":"Cerner Enviza (formerly Kantar Health)  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bulkley","sequence":"additional","affiliation":[{"name":"Cerner Enviza (formerly Kantar Health)  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana E.","family":"Matos","sequence":"additional","affiliation":[{"name":"Cerner Enviza (formerly Kantar Health)  Kansas City Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Mnif","sequence":"additional","affiliation":[{"name":"Cerner Enviza (formerly Kantar Health)  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordanna","family":"Mora","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Ko","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Meninger","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lombardelli","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals  Maidenhead UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Nance","sequence":"additional","affiliation":[{"name":"Banner Health  Gilbert Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.21037\/tgh-2020-01"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01816-2"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-012-9544-4"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000734"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0683-y"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100842"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01742-3"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-018-0178-z"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30936"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29313"},{"key":"e_1_2_14_12_1","volume-title":"Panhematin. Package insert","year":"2017"},{"key":"e_1_2_14_13_1","volume-title":"StatPearls","author":"Kothadia JP","year":"2020"},{"key":"e_1_2_14_14_1","volume-title":"Givlaari. package insert","year":"2021"},{"key":"e_1_2_14_15_1","unstructured":"Alnylam announces approval of GIVLAARI\u00ae (givosiran) in Brazil for the treatment of acute hepatic porphyria (AHP) in adults [press release].2020. Accessed January 18 2022.https:\/\/investors.alnylam.com\/sites\/default\/files\/GIVLAARI\u2010Brazil\u2010Approval\u2010Press\u2010Release.pdf"},{"key":"e_1_2_14_16_1","volume-title":"Givlaari Canada [product monograph]","year":"2020"},{"key":"e_1_2_14_17_1","unstructured":"Givlaari [summary of product characteristics].2021. Accessed January 18 2022.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/givlaari-epar-product-information_en.pdf"},{"key":"e_1_2_14_18_1","unstructured":"Givlaari solution for injection (Givosiranum).2021. Accessed July 12 2021.https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new\u2010medicines\/givlaari\u2010injektionsloesung\u2010givosiranum.html"},{"key":"e_1_2_14_19_1","unstructured":"Obtained manufacturing and marketing approval for \u201cGiblari\u201d for the treatment of acute hepatic porphyria [press release].2021. Accessed January 18 2022.https:\/\/www.alnylam.jp\/sites\/default\/files\/news\u2010articles\/Japan_Givo_Approval_Press_Release_0.pdf"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.08.006"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0319-3"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051193"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012901607040"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-005-4561-1"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001023"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2008.06.026"},{"key":"e_1_2_14_27_1","unstructured":"Quick guide to PRIME\u2010MD Patient Health Questionnaire (PHQ) PHQ9 and GAD7.1999. Accessed August 17 2021.http:\/\/www.goodmedicine.org.uk\/files\/assessment %20phq9 %20gad7 %20etc.pdf"},{"key":"e_1_2_14_28_1","first-page":"1","article-title":"Symptoms of depression among adults: United States, 2019","volume":"379","author":"Villarroel MA","year":"2020","journal-title":"NCHS Data Brief"},{"key":"e_1_2_14_29_1","first-page":"1","article-title":"Symptoms of generalized anxiety disorder among adults: United States, 2019","volume":"378","author":"Terlizzi EP","year":"2020","journal-title":"NCHS Data Brief"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(85)90004-1"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.10.005"}],"updated-by":[{"DOI":"10.1002\/jmd2.12376","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T00:00:00Z","timestamp":1688256000000}}],"container-title":["JIMD Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmd2.12343","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmd2.12343","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmd2.12343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T15:52:48Z","timestamp":1692460368000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmd2.12343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/jmd2.12343"],"URL":"https:\/\/doi.org\/10.1002\/jmd2.12343","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.1002\/jmd2.12376","asserted-by":"object"}]},"ISSN":["2192-8312","2192-8312"],"issn-type":[{"value":"2192-8312","type":"print"},{"value":"2192-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"2022-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}